Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand

Virology

Volumn 265, Issue 1, 1999, Pages 1-9

  Berman, Phillip W ^a   Huang, Wei ^a   Riddle, Lavon ^a   Gray, Alane M ^a   Wrin, Terri ^a   Vennari, Joanne ^a   Johnson, Adriana ^a   Klaussen, Michael ^a   Prashad, Hardyl ^a   Köhne, Christiane ^a   DeWit, Christina ^a   Gregory, Timothy J ^a  

^a GENENTECH INC   (United States)

Author keywords

Antibodies; CCR5; CXCR4; HIV; Neutralization; Vaccine

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RABBIT; THAILAND; UNITED STATES; VACCINE PRODUCTION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; ORYCTOLAGUS CUNICULUS; RNA VIRUSES;

EID: 0033527905     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1999.0031     Document Type: Article

References (45)

1. Alkhatib G., Combadiere, Broder C. C., Feng Y., Kennedy P. E., Murphy P. M., Berger E. A. CC CKR5: A Rantes, MIP-a, MIP-1B receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 272:1996;1955-1958.
2. Ashkenazi A., Smith D. H., Marsters S. A., Riddle L., Gregory T. J., Ho D. D., Capon D. J. Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity. Proc. Natl. Acad. Sci. USA. 88:1991;7056-7060.
3. Belshe R. B., Graham B. S., Keefer M. C., Gorse G. J., Wright P., Dolin R., Matthews T., Weinhold K., Bolognesi D. P., Sposto R., Stablein D. M., Twaddell T., Berman P. W., Gregory T., Izu A. E., Walker M. C., Fast P. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. J. Am. Med. Assoc. 272:1994;475-480.
4. Berman P. W. Apparent protection of MN-rgp120-immunized chimpanzees from infection with a primary isolate of HIV-1. Chanock R. M., Brown F., Ginsberg H. S., Norrby E. Vaccines 95: Molecular Approaches to the Control of Infectious Diseases. 1995;143-148 Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
5. Berman P. W. Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. AIDS Res. Hum. Retroviruses. 1998;S277-S289.
6. Berman P. W., Gray A. M., Wrin T., Vennari J. C., Eastman D. J., Nakamura G. R., Francis D. P., Gorse G., Schwartz D. H. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers. J. Infect. Dis. 176:1997;384-397.
7. Berman P. W., Matthews T. J., Riddle L., Champe M., Hobbs M. R., Nakamura G. R., Mercer J., Eastman D. J., Lucas C., Langlois A. J. Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1. J. Virol. 66:1992;4464-4469.
8. Berman P., Nakamura G. Adhesion mediated by intercellular adhesion molecule 1 attenuates the potency of antibodies that block HIV-1 gp160-dependent syncytium formation. AIDS Res. Hum. Retroviruses. 10:1994;585-593.
9. Cao Y., Qin L., Zhang L., Safrit J., Ho D. D. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 332:1995;201-208.
10. Choe H., Farzan M., Sun Y., Sullivan N., Rollins B., Ponath P. D., Wu L., Mackay C. R., LaRosa G., Newman W., Gerard N., Gerard C., Sodroski J. The B-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 85:1996;1135-1148.
11. Daar E. S., Li X. L., Moudgil T., Ho D. D. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc. Natl. Acad. Sci. USA. 87:1990;6574-6578.
12. Deng H. K., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., DiMarzo P., Marmon S., Sutton R. E., Hill C. M., Davis C. B., Peiper S. C., Schall T. J., Littman D. R., Landau N. R. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 381:1996;661-666.
13. + cells is mediated by chemokine receptor CC-CKR5. Nature. 381:1996;667-673.
14. D'Souza M. P., Livnat D., Bradac J. A., Bridges S. H. J. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: Performance criteria for selecting candidate antibodies for clinical trials. J. Infect. Dis. 175:1997;1056-1062.
15. Feng Y., Broder C. C., Kennedy P. E., Berger E. A. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 272:1996;872-877.
16. Fung M. S. C., Sun C. R. Y., Gordon W. L., Liou R.-S., Chang T. W., Sun W. N. C., Daar E. S., Ho D. D. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J. Virol. 66:1992;848-856.
17. Hanson C. V. Measuring vaccine-induced HIV-1 neutralization: Report of a workshop. AIDS Res. Hum. Retroviruses. 10:1994;645-648.
18. Ho D. D., McKeating J. A., Li X. L., Moudgil T., Daar E. S., Sun N.-C., Robinson J. E. Conformational epitope on gp120 important for CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J. Virol. 65:1991;489-493.
19. Kalish M. L., Baldwin A., Raktham S., Wasi C., Luo C. C., Schocetman G. The evolving molecular epidemiology of HIV-1 envelope subtypes in injecting drug users in Bangkok, Thailand: Implications for vaccine trials. AIDS. 9:1995;851-857.
20. Katzenstein D. A., Vujcic L. K., Latif A., Boulos R., Halsey N. A., Quinn T. C., Rastogi S. C., Quinnan G. V. Human immunodeficiency virus neutralizing antibodies in sera from North Americans and Africans. J. Acquired Immunodefic. Syndr. 3:1990;810-816.
21. Koot M., Vos A. H., Keet R. P., de Goede R. E., Dercksen M. W., Terpstra F. G., Coutinho R. A., Miedema F., Tersmette M. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS. 6:1992;49-54.
22. LaRosa G. J., Davide J. P., Weinhold K., Waterbury J. A., Profy A. T., Lewis J. A., Langlois A. J., Dreesman G. R., Boswell R. N., Shadduck P. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant: Corrections and clarifications. Science. 249:1991;932-935.
23. Lasky L. A., Groopman J. E., Fennie C. W., Benz P. M., Capon D. J., Dowbenko D. J., Nakamura G. R., Nunes W. M., Renz M. E., Berman P. W. Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science. 233:1986;209-212.
24. + T-cell clone (PM-1): Failure to downregulate CD4 and to interfere with cell line tropic HIV-1. J. Virol. 69:1995;3712-3820.
25. Mascola J. R., Louwagie J., McCutchan F. E., Fischer C. L., Hegerich P. A., Wagner K. F., Fowler A. K., McNeil J. G., Burke D. S. Two antigenically distinct subtypes of human immunodeficiency virus type 1: Viral genotype predicts neutralization serotype. J. Infect. Dis. 169:1994;48-54.
26. Mascola J. R., Snyder S. W., Weislow O. S., Belay S. M., Belshe R. B., Schwartz D. H., Clements M. L., Dolin R., Graham B. S., Gorse G. J., Keefer M. C., McElrath M. J., Walker M. C., Wagner K. F., McNeil J. G., McCutchan F. E., Burke D. S. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J. Infect. Dis. 173:1996;340-348.
27. McCutchan F. E., Hegerich P. A., Brennan T. P., Phanuphak P., Singharaj P., Jugsudee A., Berman P. W., Gray A. M., Fowler A. K., Burke D. S. Genetic variants of HIV-1 in Thailand. AIDS Res. Hum. Retroviruses. 8:1992;1887-1895.
28. Meyerhans A., Cheynier R., Albert J., Seth M., Kwok S., Sninsky J., Morfelddt-Manson L., Asjo B., Wain-Hobson S. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell. 58:1989;901-910.
29. Migasena, S, Suntharasamai, P, Pitisuttithum, P, Kitayaporn, D, Wasi, C, Huang, W, Vanichseni, S, Koompong, C, Kaewkungwal, J, Raktham, S, Ippolito, T, Hansen, C, Gregory, T, Heyward, W. L, Berman, P, and, Francis, D. AIDSVAX (MN) in Bangkok injecting drug users. I. A report on safety and immunogenicity, including macrophage-tropic virus neutralization, AIDS Res. Hum. Retroviruses, 15, in press.
30. Moore J. P., Cao Y., Quing L., Sattentau Q. J., Pyati J., Koduri R., Robinson J., Barbas C. F. III, Burton D. R., Ho D. D. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69:1995;101-109.
31. Moore J. P., Cao Y., Leu J., Qin L., Korber B., Ho D. D. Inter- and Intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization subtypes but partially correspond to antigenic serotypes. J. Virol. 70:1996;427-444.
32. Murphy E., Korber B., Georges-Courbot M. C., Tou B., Pinter A., Cook D. Diversity of V3 region sequences of human immunodeficiency virus type 1 from the Central African Republic. AIDS Res. Hum. Retroviruses. 9:1993;997-1005.
33. Myers G., Korber B., Wain-Hobson S., Jeang K. T., Henderson L. E., Pavlakis G. N. Human Retroviruses and AIDS. 1994;Los Alamos National Laboratory, Los Alamos.
34. Nakamura G., Byrn R., Rosenthal K., Porter J. P., Hobbs M. R., Riddle L., Eastman D. J., Dowbenko D., Gregory T., Fendly B., Berman P. W. Monoclonal antibodies to the extracellular domain of HIV-1IIIB gp160 that neutralize infectivity, block binding to CD4, and react with diverse isolates. AIDS Res. Hum. Retroviruses. 8:1992;1875-1885.
35. Nakamura G. R., Byrn R., Wilkes D. M., Hobbs M. R., Wessling H. C., Norcross M. A., Fendly B. M., Berman P. W. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1. J. Virol. 67:1993;6179-6191.
36. Nkengasong J. N., Janssens W., Heyndrickx L., Fransen K., Ndumbe P. M., Motte J., Leonaers A., Ngolle M., Ayuk J., Piot P., van der Groen G. Genotypic subtypes of HIV-1 in Cameroon. AIDS. 8:1994;1405-1412.
37. Oberlin E., Amara A., Bachelerie F., Bessia C., Virelizier J., Arenzana-Seisdedos F., Schwartz O., Heard J., Clark-Lewi I., Legler D., Loetscher M., Baggiolini M., Moser B. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature. 382:1996;833-835.
38. Robertson G. A., Kostek B. M., Schlief W. A., Lewis J. A., Emini E. A. A microtiter cell culture assay for the determination of anti-human immunodeficiency virus neutralizing antibody activity. J. Virol. Methods. 20:1988;195-202.
39. Schwartz D. H., Gorse G., Clements M. L., Belshe R., Izu A., Duliege A.-M., Berman P., Twaddell T., Stablein D., Spostos R., Siliciano R., Matthews T. Induction of HIV-1 neutralizing and syncytium-inhibiting antibodies in seronegative recipients of HIV-1 IIIB rgp120 subunit vaccine. Lancet. 342:1993;69-73.
40. Subbarao S., Limpakarnjanarat K., Mastro T. D., Bhumisawasdi J., Warachit P., Jayavasu C., Young N., Luo C.-C., Shaffer N., Kalish M. L., Schocetman G. HIV-1 type1 in Thailand, 1994-1995: Persistence of two subtypes with low genetic diversity. AIDS Res. Hum. Retroviruses. 4:1998;319-327.
41. Trkola A., Pomales A. B., Yuan H., Korber B., Maddon P. J., Allaway G. P., Katinger H., Barbas C. F. III, Burton D. R., Ho D. D., Moore J. P. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69:1995;6609-6617.
42. Weiss R. A., Clapham P. R., Weber J. N., Dalgleish A. G., Lasky L. A., Berman P. W. Variable and conserved neutralization antigens of human immunodeficiency virus. Nature. 324:1986;572-575.
43. Wrin T., Loh T. P., Vennari J. C., Schuitemaker H., Nunberg J. H. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J. Virol. 69:1995;39-48.
44. Yu X. F., Wang Z., Beyrer C., Celantano D. D., Khamboonruang C., Allen E., Nelson K. Phenotypic and genotypic characteristics of human immunodeficiency virus type 1 from patients with AIDS in Northern Thailand. J. Virol. 69:1995;4649-4655.
45. Zolla-Pazner S., Sharp S. A resting cell assay for improved detection of antibody mediated neutralization of HIV type 1 primary isolates. AIDS Res. Hum. Retroviruses. 11:1995;1449-1458.